+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Cancer Monoclonal Antibody Partnering Terms and Agreements 2014-2020

  • ID: 2336340
  • Report
  • May 2020
  • Region: Global
  • 300 Pages
  • CurrentPartnering
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now
Antibody partnering activity rises by 13.6%, read about this and other trends in the antibody industry.

FEATURED COMPANIES

  • 3SBio
  • Aeglea BioTherapeutics
  • Apeiron Biologics
  • Atlab Pharma
  • BioInvent
  • Cantargia
  • MORE
The Global Cancer Monoclonal Antibody Partnering 2014-2020: Deal trends, players, financials and forecasts report provides an understanding and access to the cancer monoclonal antibody partnering deals and agreements entered into by the worlds leading healthcare companies.
  • Trends in cancer monoclonal antibody partnering deals
  • Most active companies in cancer monoclonal antibody partnering
  • Disclosed headlines, upfronts, milestones and royalties by stage of development
  • Cancer monoclonal antibody partnering contract documents
  • Top cancer monoclonal antibody deals by value
This report provides details of the latest Cancer monoclonal antibody agreements announced in the healthcare sectors.

This report provides details of the latest antibody agreements announced in the healthcare sectors, covering:
  • Monoclonal antibodies
  • Murine mAb
  • Chimeric mAb
  • Humanized mAb
  • Human aAb
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all Cancer monoclonal antibody partnering deals announced since Jan 2014, including financial terms where available, including links to online deal records of actual Cancer monoclonal antibody partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of Cancer monoclonal antibody dealmaking and business activities.
  • Chapter 1 provides an introduction to the report.
  • Chapter 2 provides an overview of the trends in Cancer monoclonal antibody dealmaking since 2014, including details of average headline, upfront, milestone and royalty terms.
  • Chapter 3 provides a review of the leading Cancer monoclonal antibody deals since 2014. Deals are listed by headline value, signed by big pharma, most active Cancer monoclonal antibody dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
  • Chapter 4 provides a comprehensive listing of the top 25 most active companies in Cancer monoclonal antibody dealmaking with a brief summary followed by a comprehensive listing of Cancer monoclonal antibody deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
  • Chapter 5 provides a comprehensive and detailed review of Cancer monoclonal antibody partnering deals signed and announced since Jan 2014, where a contract document is available in the public domain. The - Chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
  • Chapter 6 provides a comprehensive and detailed review of Cancer monoclonal antibody partnering deals signed and announced since Jan 2014. The - Chapter is organized by specific Cancer monoclonal antibody technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided organized by Cancer monoclonal antibody partnering company A-Z, deal type definitions and Cancer monoclonal antibody partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Cancer monoclonal antibody partnering and dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Cancer monoclonal antibody technologies and products.

Key benefits

Global Cancer Monoclonal Antibody Partnering Terms & Agreements provides the reader with the following key benefits:
  • In-depth understanding of cancer monoclonal antibody deal trends since 2014
  • Access to headline, upfront, milestone and royalty data
  • Access to the structure of cancer monoclonal antibody agreements with numerous real life case studies
  • Comprehensive access to over 450 actual cancer monoclonal antibody deals entered into by the world’s biopharma companies
  • Identify most active companies in cancer monoclonal antibody partnering
  • Insight into the terms included in a cancer monoclonal antibody agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies
  • Spot the emerging companies in the cancer monoclonal antibody area
Report scope

Global Cancer Monoclonal Antibody Partnering Terms & Agreements is intended to provide the reader with an in-depth understanding and access to cancer monoclonal antibody trends and structure of deals entered into by leading companies worldwide.

Cancer Monoclonal Antibody Partnering Terms & Agreements includes:
  • Trends in cancer monoclonal antibody dealmaking in the biopharma industry since 2014
  • Analysis of cancer monoclonal antibody deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to over 450 cancer monoclonal antibody deal records
  • The leading cancer monoclonal antibody deals by value since 2014
In Cancer Monoclonal Antibody Partnering Terms & Agreements, the available deals are listed by:
  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific oncology therapy target
  • Monoclonal antibody type
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Cancer Monoclonal Antibody Partnering Terms & Agreements report provides comprehensive access to available deals and contract documents for over 450 cancer monoclonal antibody deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • 3SBio
  • Aeglea BioTherapeutics
  • Apeiron Biologics
  • Atlab Pharma
  • BioInvent
  • Cantargia
  • MORE
Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in Cancer monoclonal antibody dealmaking
2.1. Introduction
2.2. Cancer monoclonal antibody partnering over the years
2.3. Most active Cancer monoclonal antibody dealmakers
2.4. Cancer monoclonal antibody partnering by deal type
2.5. Cancer monoclonal antibody partnering by therapy area
2.6. Deal terms for Cancer monoclonal antibody partnering
2.6.1 Cancer monoclonal antibody partnering headline values
2.6.2 Cancer monoclonal antibody deal upfront payments
2.6.3 Cancer monoclonal antibody deal milestone payments
2.6.4 Cancer monoclonal antibody royalty rates

Chapter 3 – Leading Cancer monoclonal antibody deals
3.1. Introduction
3.2. Top Cancer monoclonal antibody deals by value

Chapter 4 – Most active Cancer monoclonal antibody dealmakers
4.1. Introduction
4.2. Most active Cancer monoclonal antibody dealmakers
4.3. Most active Cancer monoclonal antibody partnering company profiles

Chapter 5 – Cancer monoclonal antibody contracts dealmaking directory
5.1. Introduction
5.2. Cancer monoclonal antibody contracts dealmaking directory

Chapter 6 – Cancer monoclonal antibody dealmaking by technology type
  • Monoclonal antibodies
  • Chimeric mAb
  • Humanized mAb
  • Human mAb
  • Murine mAb
Chapter 7 – Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

Appendices
  • Appendix 1 – Cancer monoclonal antibody deals by company A-Z
  • Appendix 2 – Cancer monoclonal antibody deals by stage of development
  • Discovery
  • Preclinical
  • Phase I
  • Phase II
  • Phase III
  • Regulatory
  • Marketed
  • Formulation
  • Appendix 3 – Cancer monoclonal antibody deals by deal type
  • Asset purchase
  • Assignment
  • Bigpharma outlicensing
  • Co-development
  • Collaborative R&D
  • Co-market
  • Co-promotion
  • CRADA
  • Development
  • Distribution
  • Equity purchase
  • Evaluation
  • Grant
  • Joint venture
  • Licensing
  • Loan
  • Manufacturing
  • Marketing
  • Material transfer
  • Option
  • Promotion
  • Research
  • Settlement
  • Spin out
  • Sub-license
  • Supply
  • Technology transfer
  • Termination
  • Appendix 4 – Cancer monoclonal antibody deals by therapy area
  • Appendix 5 –Deal type definitions
Table of figures
Figure 1: Therapeutic antibody definitions
Figure 2: Cancer monoclonal antibody partnering since 2014
Figure 3: Active Cancer monoclonal antibody dealmaking activity since 2014
Figure 4: Cancer monoclonal antibody partnering by deal type since 2014
Figure 5: Cancer monoclonal antibody partnering by disease type since 2014
Figure 6: Cancer monoclonal antibody deals with a headline value
Figure 7: Cancer monoclonal antibody deals with an upfront value
Figure 8: Cancer monoclonal antibody deals with a milestone value
Figure 9: Cancer monoclonal antibody deals with a royalty rate value
Figure 10: Top Cancer monoclonal antibody deals by value since 2014
Figure 11: Most active Cancer monoclonal antibody dealmakers since 2014
Figure 12: Online partnering resources
Figure 13: Forthcoming partnering events
Note: Product cover images may vary from those shown
3 of 4
  • 3SBio
  • 4D Pharma
  • Abbvie
  • AbClon
  • Abpro
  • Abzena
  • Accord Healthcare
  • Acerta Pharma
  • Actinium Pharmaceuticals
  • Adaptimmune
  • Adaptive Biotechnologies
  • Adlai Nortye
  • Aduro BioTech
  • Advantagene
  • Advaxis
  • Aeglea BioTherapeutics
  • AffaMed Therapeutics
  • Affimed Therapeutics
  • Affinita Biotech
  • AGC Biologics
  • Agenus Bio
  • Alligator Bioscience
  • Alvogen
  • Ambrx
  • Amgen
  • Amneal Pharmaceuticals
  • AnaptysBio
  • Anthera Pharmaceuticals
  • Antigen Express
  • Apceth
  • Apeiron Biologics
  • Aperion Biologics
  • Apexigen
  • Arcus Biosciences
  • arGEN-X
  • argenx
  • Array Biopharma
  • Ascenion
  • Ascentage Pharma
  • Aslan Pharma
  • Astellas Pharma
  • Astex Pharmaceuticals
  • AstraZeneca
  • Atara Biotherapeutics
  • Athenex
  • Atlab Pharma
  • AVEO Oncology
  • Aytu BioScience
  • Basilea Pharmaceutica
  • Bavarian Nordic
  • Baxalta
  • Bayer
  • BeiGene
  • BerGenBio
  • Biametrics
  • Bio-Thera Solutions
  • BioAtla
  • Bioceros
  • BiocerOX Products
  • Biodesix
  • Bio Farma
  • BioInvent
  • BiolineRX
  • BioMarker Strategies
  • Biomunex Pharmaceuticals
  • BioNTech
  • Biothera
  • BioXcel
  • BliNK Biomedical
  • BliNK Therapeutics
  • Boehringer Ingelheim
  • Bpifrance
  • Bristol-Myers Squibb
  • C-Bridge Capital
  • Calithera Biosciences
  • Cancer Prevention and Research Institute of Texas
  • Cancer Research Technology
  • Cancer Research UK
  • Cantargia
  • CBT Pharmaceuticals
  • CDI Laboratories
  • Celgene
  • Celldex Therapeutics
  • Cell Signaling Technology
  • Celltrion
  • Centre for Drug Research and Development (CDRD)
  • Checkmate Pharmaceuticals
  • Chiome Bioscience
  • Cilag AG
  • Cipla
  • Clal Biotech
  • Clinica Universidad Navarra
  • Clovis Oncology
  • CMAB Biopharma
  • CMC Biologics
  • Cold Genesys
Note: Product cover images may vary from those shown
4 of 4
  • The publisher reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
  • The publisher reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
  • The publisher analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
  • The publisher reports source deal data from our proprietary deals and alliances database. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal.
  • The data in the deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

The publisher provides comprehensive coverage of the following partnering or deal types:

  • Asset purchase
  • Assignment
  • Co-development
  • Co-market
  • Co-promotion
  • Collaborative R&D
  • Contract service
  • CRADA
  • Cross-licensing
  • Development
  • Distribution
  • Equity purchase
  • Evaluation
  • Grant
  • Joint venture
  • Licensing
  • Loan
  • Manufacturing
  • Marketing
  • Option
  • Promotion
  • Research
  • Royalty financing
  • Settlement
  • Spin out
  • Sub license
  • Supply
  • Termination
  • Warrant

Every deal record is fully categorized and includes the following data, where available:

  • Industry sector
  • Therapy areas
  • Technology type
  • Deal components
  • Financial terms
  • Stage of development
  • Exclusivity
  • Asset type
  • Geographic focus
  • Excluded geography
  • Company press release
  • SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

 

 

Loading
LOADING...

Adroll
adroll